Aarti Drugs Ltd
Aarti Drugs Ltd (AARTIDRUGS) last reported results for the quarter ended Jun 2026, with sales of ₹703 crore and net profit of ₹50 crore. The stock last traded at ₹416, a market capitalisation of ₹3,796 crore, on a P/E of 19.7. Over the past 52 weeks the stock has ranged between ₹319 and ₹534. Figures are as of 6 Oct 2026 and are not real time.
Aarti Drugs Ltd share price and key metrics
- Current price
- ₹416
- Market cap
- ₹3,796 cr
- Stock P/E
- 19.7
- Book value
- ₹170
- ROE
- 13.4%
- ROCE
- 12.0%
- Dividend yield
- 0.48%
- 52w high / low
- 534/319
Metrics as of 6 Oct 2026. Not real time.
Track Aarti Drugs Ltd
Cruxal reads every Aarti Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Aarti Drugs Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 4%
- 3 Years
- -2%
- TTM
- 11%
- 10 Years
- 11%
- 5 Years
- -7%
- 3 Years
- 5%
- TTM
- 2%
- 10 Years
- 10%
- 5 Years
- -8%
- 3 Years
- -7%
- 1 Year
- -17%
- 10 Years
- 18%
- 5 Years
- 15%
- 3 Years
- 13%
- Last Year
- 13%
Aarti Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹703 cr, up 19.0% from ₹591 cr a year earlier. Net profit was ₹50 cr, down 7.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 |
| Expenses | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 |
| Operating profit | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 |
| OPM % | 11% | 11% | 14% | 13% | 13% | 9% | 13% | 14% |
| Other income | 1 | 12 | 2 | 0 | 0 | 1 | 1 | -1 |
| Interest | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 |
| Depreciation | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 |
| Profit before tax | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 |
| Tax % | 24% | 27% | 12% | -6% | 25% | -40% | 21% | 28% |
| Net profit | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 |
| EPS (₹) | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | 5.50 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aarti Drugs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | 2,716 | 2,529 | 2,387 | 2,565 | 2,678 |
| Operating profit | 190 | 202 | 211 | 266 | 440 | 333 | 309 | 321 | 290 | 312 | 333 |
| OPM % | 16% | 16% | 14% | 15% | 20% | 13% | 11% | 13% | 12% | 12% | 12% |
| Net profit | 82 | 82 | 90 | 141 | 280 | 205 | 166 | 172 | 168 | 195 | 191 |
| EPS (₹) | 8.57 | 8.73 | 9.52 | 15.17 | 30.09 | 22.14 | 17.96 | 18.65 | 18.42 | 21.36 | 20.95 |
TTM is the trailing twelve months to the most recent quarter.
Aarti Drugs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
| Reserves | 376 | 432 | 520 | 629 | 820 | 944 | 1,100 | 1,190 | 1,278 | 1,458 |
| Borrowings | 480 | 546 | 507 | 389 | 351 | 543 | 609 | 564 | 615 | 577 |
| Other liabilities | 311 | 388 | 405 | 535 | 502 | 629 | 620 | 587 | 591 | 690 |
| Total liabilities | 1,191 | 1,389 | 1,455 | 1,576 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 | 2,815 |
| Fixed assets | 581 | 602 | 625 | 644 | 665 | 690 | 676 | 811 | 866 | 1,086 |
| CWIP | 14 | 28 | 33 | 12 | 19 | 77 | 210 | 261 | 330 | 214 |
| Investments | 12 | 11 | 12 | 13 | 17 | 19 | 19 | 20 | 22 | 27 |
| Other assets | 584 | 748 | 785 | 907 | 1,064 | 1,422 | 1,516 | 1,340 | 1,356 | 1,488 |
| Total assets | 1,191 | 1,389 | 1,455 | 1,576 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 | 2,815 |
As reported by the company. Total assets equal total liabilities by construction.
Aarti Drugs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 175 | 70 | 143 | 251 | 155 | 70 | 133 | 359 | 245 | 254 |
| Cash from investing | -107 | -74 | -62 | -33 | -72 | -150 | -164 | -224 | -165 | -173 |
| Cash from financing | -68 | 4 | -80 | -215 | -81 | 92 | 17 | -136 | -82 | -77 |
| Net cash flow | -0 | 0 | 1 | 2 | 2 | 13 | -14 | -1 | -2 | 3 |
| Free cash flow | 68 | -5 | 80 | 214 | 78 | -82 | -31 | 133 | 67 | 80 |
| CFO / operating profit | 103% | 47% | 82% | 110% | 57% | 46% | 62% | 131% | 103% | 80% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Aarti Drugs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 18% | 17% | 17% | 21% | 34% | 21% | 15% | 15% | 13% | 12% |
| Debtor days | 91 | 110 | 107 | 99 | 94 | 110 | 116 | 102 | 115 | 118 |
| Inventory days | 100 | 132 | 86 | 102 | 117 | 115 | 101 | 107 | 114 | 112 |
| Days payable | 94 | 123 | 85 | 104 | 93 | 103 | 94 | 94 | 100 | 109 |
| Cash conversion cycle | 97 | 119 | 109 | 97 | 118 | 123 | 123 | 115 | 129 | 121 |
| Working capital days | 22 | 33 | 44 | 54 | 77 | 63 | 72 | 74 | 76 | 76 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Aarti Drugs Ltd shareholding pattern
Promoters held 54.43% at Jun 2026, down from 55.23% at Jun 2025. FIIs 1.52% and DIIs 10.29%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.64% | 55.38% | 55.48% | 55.23% | 54.72% | 55.03% | 55.03% | 54.43% |
| FIIs | 2.50% | 2.28% | 2.25% | 2.26% | 2.68% | 2.15% | 1.57% | 1.52% |
| DIIs | 7.83% | 8.77% | 9.70% | 9.94% | 9.90% | 10.12% | 10.22% | 10.29% |
| Public | 34.01% | 33.58% | 32.57% | 32.58% | 32.70% | 32.71% | 33.19% | 33.76% |
| No. of shareholders | 1,90,281 | 1,76,006 | 1,69,761 | 1,60,260 | 1,52,252 | 1,48,363 | 1,44,946 | 1,43,476 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Aarti Drugs Ltd corporate filings
- Aarti Drugs Ltd Intimates Crisil ESG Rating Update under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: The company has filed an intimation regarding its ESG rating by Crisil, as per SEBI LODR…
Read the full analysis - Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018Company Updatelow impact
- Aarti Drugs Ltd discloses details of authorized persons under Regulation 30(5) of SEBI LODR, 2015Company Updatelow impact
Cruxal's analysis: The company has provided updated details of authorized persons as per regulatory…
Read the full analysis - Aarti Drugs Announces Leadership Transition and Management Changes, No Immediate Financial ImpactCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Limited has disclosed the resignation of Chairman, Managing Director, and CEO…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Aarti Drugs Limited Announces Leadership Transition and Board ReconstitutionsCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Limited has formalized a leadership transition, with Adhish Prakash Patil…
Read the full analysis - Aarti Drugs Limited shareholders approve Performance Stock Option Plan 2026 and key management appointments at 41st AGMAGM/EGMmedium impact
Cruxal's analysis: Aarti Drugs Limited has successfully concluded its 41st Annual General Meeting, where…
Read the full analysis - Aarti Drugs Limited Investor Presentation Highlights Strategic Pivot to Regulated Markets and Capacity ExpansionCompany Updatehigh impact
Cruxal's analysis: Aarti Drugs Limited released its investor presentation for the 41st Annual General…
Read the full analysis - Aarti Drugs Limited concludes 41st Annual General Meeting; announces leadership transition and new performance stock option planAGM/EGMlow impact
Cruxal's analysis: Aarti Drugs Limited has successfully concluded its 41st Annual General Meeting, where…
Read the full analysis - Aarti Drugs Ltd publishes mandatory newspaper notice regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has fulfilled its statutory obligation under Regulation 30 of the SEBI…
Read the full analysis - Aarti Drugs Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Aarti Drugs Ltd has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Aarti Drugs Limited Announces 41st Annual General Meeting and Leadership TransitionAGM/EGMhigh impact
Cruxal's analysis: Aarti Drugs Limited has scheduled its 41st Annual General Meeting for September 26, 2026…
Read the full analysis - Aarti Drugs Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Aarti Drugs Ltd has filed its Annual Report for the financial year 2025-26 as per…
Read the full analysis - Aarti Drugs Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Aarti Drugs Limited approves Performance Stock Option Plan 2026 for up to 8 lakh equity sharesBoard Meetinglow impact
Cruxal's analysis: Aarti Drugs Limited has announced the approval of the 'Aarti Drugs Limited Performance…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Aarti Drugs Limited schedules board meeting to consider Performance Stock Option Plan 2026Board Meetinglow impact
Cruxal's analysis: Aarti Drugs Limited has announced a board meeting scheduled for August 27, 2026, to…
Read the full analysis - Aarti Drugs Ltd announces intimation of analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has filed an intimation regarding an upcoming analyst/institutional…
Read the full analysis - Aarti Drugs Ltd files routine regulatory disclosure under SEBI Listing RegulationsCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Aarti Drugs Q1 FY27 Earnings Call Highlights: 19% Revenue Growth and Margin Expansion Driven by Sayakha Facility Ramp-upCompany Updatehigh impact
Cruxal's analysis: Aarti Drugs Limited reported a strong start to FY27 with consolidated revenue of 703.6…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.